Progyny Sets Q2 Revenue Outlook at $342M-$355M
summarizeSummary
Progyny has issued its second-quarter 2026 revenue guidance, projecting figures between $342 million and $355 million. This specific quarterly outlook provides more granular detail following the company's broader 'Positive 2026 Guidance' announced in February. Forward-looking revenue guidance is a critical data point for investors, directly influencing analyst models and market expectations for the company's near-term performance. Traders will now assess this range against current consensus estimates to determine potential stock price movements. The market will closely watch for any updates or deviations from this guidance in the upcoming earnings report.
At the time of this announcement, PGNY was trading at $22.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $16.10 to $28.75. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.